Compare Stocks: AKRO, EXEL, ASND, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$54.65 +0.2%	$54.50	$37.28 ▼ $57.35	$4.50B	-0.4	1.86 million shs	15.31 million shs
ASND Ascendis Pharma A/S	$229.11 +1.7%	$244.45	$186.05 ▼ $282.15	$14.26B	0.38	701,189 shs	233,850 shs
EXEL Exelixis	$62.39 +0.3%	$56.89	$33.76 ▼ $63.39	$15.45B	0.47	2.60 million shs	249,491 shs
HALO Halozyme Therapeutics	$122.41 +0.5%	$109.06	$61.22 ▼ $123.51	$13.90B	0.88	1.94 million shs	221,221 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	0.00%	0.00%	0.00%	0.00%	+1.50%
ASND Ascendis Pharma A/S	0.00%	-1.74%	-4.85%	-10.53%	+7.01%
EXEL Exelixis	0.00%	+3.96%	+6.63%	+12.07%	+58.55%
HALO Halozyme Therapeutics	0.00%	+10.34%	+8.35%	+58.05%	+81.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$54.65 +0.2%	$54.50	$37.28 ▼ $57.35	$4.50B	-0.4	1.86 million shs	15.31 million shs
ASND Ascendis Pharma A/S	$229.11 +1.7%	$244.45	$186.05 ▼ $282.15	$14.26B	0.38	701,189 shs	233,850 shs
EXEL Exelixis	$62.39 +0.3%	$56.89	$33.76 ▼ $63.39	$15.45B	0.47	2.60 million shs	249,491 shs
HALO Halozyme Therapeutics	$122.41 +0.5%	$109.06	$61.22 ▼ $123.51	$13.90B	0.88	1.94 million shs	221,221 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	0.00%	0.00%	0.00%	0.00%	+1.50%
ASND Ascendis Pharma A/S	0.00%	-1.74%	-4.85%	-10.53%	+7.01%
EXEL Exelixis	0.00%	+3.96%	+6.63%	+12.07%	+58.55%
HALO Halozyme Therapeutics	0.00%	+10.34%	+8.35%	+58.05%	+81.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	N/A	N/A
ASND Ascendis Pharma A/S	3.00	Buy	$309.26	34.99% Upside
EXEL Exelixis	2.35	Hold	$51.50	-17.45% Downside
HALO Halozyme Therapeutics	2.77	Moderate Buy	$99.55	-18.68% Downside

Current Analyst Ratings Breakdown

Latest AKRO, EXEL, ASND, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/19/2026	EXEL Exelixis	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Outperform	$55.00 ➝ $65.00
10/16/2026	HALO Halozyme Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$130.00
10/15/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$307.00 ➝ $269.00
10/13/2026	ASND Ascendis Pharma A/S	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C)
10/13/2026	HALO Halozyme Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/13/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/9/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$45.00 ➝ $51.00
10/8/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (A-) ➝ Buy (A)
10/8/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Perform	$46.00 ➝ $45.00
10/8/2026	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$70.00 ➝ $78.00

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
ASND Ascendis Pharma A/S	$814.57M	17.55	N/A	N/A	($2.97) per share	-77.14
EXEL Exelixis	$2.32B	6.66	$3.03 per share	20.56	$8.06 per share	7.74
HALO Halozyme Therapeutics	$1.66B	8.35	$4.79 per share	25.54	$0.42 per share	291.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.94	N/A	N/A	N/A	N/A	-15.86%	-14.78%	N/A
ASND Ascendis Pharma A/S	-$258M	$12.89	17.73	25.60	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	19.60	16.82	1.75	35.33%	42.17%	31.76%	10/29/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	36.55	12.50	0.46	24.86%	260.98%	23.91%	11/2/2026 (Estimated)

Latest AKRO, EXEL, ASND, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ASND Ascendis Pharma A/S	$0.9080	N/A	N/A	N/A	$411.29 million	N/A
11/2/2026	Q3 2026	HALO Halozyme Therapeutics	$2.30	N/A	N/A	N/A	$490.85 million	N/A
10/29/2026	Q3 2026	EXEL Exelixis	$0.8790	N/A	N/A	N/A	$646.95 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	N/A	15.84	15.83
ASND Ascendis Pharma A/S	0.27	2.99	2.32
EXEL Exelixis	N/A	3.46	3.38
HALO Halozyme Therapeutics	13.50	2.71	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
ASND Ascendis Pharma A/S	N/A
EXEL Exelixis	85.27%
HALO Halozyme Therapeutics	97.79%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
ASND Ascendis Pharma A/S	40.00%
EXEL Exelixis	2.60%
HALO Halozyme Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	82.32 million	76.50 million	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable

AKRO, EXEL, ASND, and HALO Headlines

Recent News About These Companies

Halozyme Therapeutics stock closed at USD 121.84, 0.49 percent below its 52-week high

October 18 at 6:36 PM | ad-hoc-news.deA

Assenagon Asset Management S.A. Sells 600,777 Shares of Halozyme Therapeutics, Inc. $HALO

October 18 at 3:12 AM | marketbeat.com

5 Stocks to Buy Using the Relative Price Strength Strategy

October 16 at 3:10 PM | zacks.com

H.C. Wainwright Reaffirms Their Buy Rating on Halozyme (HALO)

October 16 at 1:19 PM | theglobeandmail.com

Is Expanded Argenx Deal Altering The Investment Case For Halozyme Therapeutics (HALO)?

October 16 at 8:18 AM | finance.yahoo.com

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

October 16 at 6:30 AM | zacks.com

Halozyme Therapeutics (NASDAQ:HALO) Stock Jumps 5.9% After Analyst Upgrade

October 16 at 1:52 AM | americanbankingnews.com

Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance

October 15, 2026 | msn.com

Halozyme Therapeutics (NASDAQ:HALO) Upgraded at Zacks Research

October 15, 2026 | marketbeat.com

Halozyme Therapeutics (NASDAQ:HALO) Reaches New 1-Year High - Here's What Happened

October 15, 2026 | marketbeat.com

TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock

October 15, 2026 | americanbankingnews.com

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

October 14, 2026 | zacks.com

Halozyme Therapeutics stock hits all-time high at 116.85 USD

October 14, 2026 | au.investing.com

Halozyme Therapeutics gains as partner-drug approval, patent win, and bullish analyst call lift sentiment

October 14, 2026 | quiverquant.comQ

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Up 5.9% After Analyst Upgrade

October 14, 2026 | marketbeat.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

October 14, 2026 | zacks.com

Halozyme Therapeutics, Inc. $HALO Stock: NorthCrest Asset Manangement LLC Increases Position

October 14, 2026 | marketbeat.com

Halozyme Therapeutics (NASDAQ:HALO) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

October 14, 2026 | marketbeat.com

Halozyme Therapeutics, Inc. $HALO Shares Purchased by Cooper Investors PTY Ltd.

October 13, 2026 | marketbeat.com

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

October 13, 2026 | zacks.com

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, TD Cowen Analyst Says

October 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKRO, EXEL, ASND, and HALO Company Descriptions

Akero Therapeutics NASDAQ:AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Ascendis Pharma A/S NASDAQ:ASND

$229.11 +3.86 (+1.71%)

As of 10:50 AM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis NASDAQ:EXEL

$62.39 +0.16 (+0.26%)

As of 10:50 AM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Halozyme Therapeutics NASDAQ:HALO

$122.41 +0.57 (+0.47%)

As of 10:50 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKRO, EXEL, ASND, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKRO, EXEL, ASND, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKRO, EXEL, ASND, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKRO, EXEL, ASND, and HALO Company Descriptions

Akero Therapeutics NASDAQ:AKRO

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKRO, EXEL, ASND, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKRO, EXEL, ASND, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKRO, EXEL, ASND, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKRO, EXEL, ASND, and HALO Company Descriptions

Akero Therapeutics NASDAQ:AKRO

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools